vepalimomab
mAbexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Amine oxidase, copper containingINHIBITOR
AOC3 inhibitor
Inhibits lymphocyte binding to AOC3 (VAP-1) expressed in high endothelial venules (HEV).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108167 ↗
Also known as
- vepalimomab